scroll to top
0

EBSCO Auth Banner

Let's find your institution. Click here.

Advanced Search Results For "DISEASE progression"

1 - 10 of 279,514 results for
 "DISEASE progression"
Results per page:

Identification of potential pathways and biomarkers linked to progression in ALS.

Publication Type: Academic Journal

Source(s): Annals of clinical and translational neurology [Ann Clin Transl Neurol] 2023 Feb; Vol. 10 (2), pp. 150-165. Date of Electronic Publication: 2022 Dec 19.

Abstract: Objective: To identify potential diagnostic and prognostic biomarkers for clinical management and clinical trials in amyotrophic lateral sclerosis.Methods: We analysed proteomics data of ALS patient-induced pluripotent stem cell-derived motor neurons a...

Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.

Publication Type: Academic Journal

Source(s): The journal of prevention of Alzheimer's disease [J Prev Alzheimers Dis] 2023; Vol. 10 (2), pp. 212-222.

Abstract: Background: Progression in Alzheimer's disease manifests as changes in multiple biomarker, cognitive, and functional endpoints. Disease progression modeling can be used to integrate these multiple measures into a synthesized metric of where a patient l...

Dipping Status, Ambulatory Blood Pressure Control, Cardiovascular Disease, and Kidney Disease Progression: A Multicenter Cohort Study of CKD.

Publication Type: Academic Journal

Source(s): American journal of kidney diseases : the official journal of the National Kidney Foundation [Am J Kidney Dis] 2023 Jan; Vol. 81 (1), pp. 15-24.e1. Date of Electronic Publication: 2022 Jun 13.

Abstract: Rationale & Objective: Ambulatory blood pressure (BP) monitoring allows concurrent evaluation of BP control and nocturnal BP dipping status, both related to adverse outcomes. However, few studies have assessed the prognostic role of combining informati...

Deletion of equilibrative nucleoside transporter 2 disturbs energy metabolism and exacerbates disease progression in an experimental model of Huntington's disease.

Publication Type: Academic Journal

Source(s): Neurobiology of disease [Neurobiol Dis] 2023 Feb; Vol. 177, pp. 106004. Date of Electronic Publication: 2023 Jan 17.

Abstract: Huntington's disease (HD) is an autosomal dominant neurodegenerative disease, characterized by motor dysfunction and abnormal energy metabolism. Equilibrative nucleoside transporter 1 (ENT1) and ENT2 are the major nucleoside transporters in cellular pl...

Blood Markers of Inflammation, Neurodegeneration, and Cardiovascular Risk in Early Parkinson's Disease.

Publication Type: Academic Journal

Source(s): Movement disorders : official journal of the Movement Disorder Society [Mov Disord] 2023 Jan; Vol. 38 (1), pp. 68-81. Date of Electronic Publication: 2022 Oct 20.

Abstract: Background: Recent studies point toward a significant impact of cardiovascular processes and inflammation on Parkinson's disease (PD) progression.Objective: The aim of this study was to assess established markers of neuronal function, inflammation, and...

MC-RVAE: Multi-channel recurrent variational autoencoder for multimodal Alzheimer's disease progression modelling.

Publication Type: Academic Journal

Source(s): NeuroImage [Neuroimage] 2023 Mar; Vol. 268, pp. 119892. Date of Electronic Publication: 2023 Jan 20.

Abstract: The progression of neurodegenerative diseases, such as Alzheimer's Disease, is the result of complex mechanisms interacting across multiple spatial and temporal scales. Understanding and predicting the longitudinal course of the disease requires harnes...

Time Taken for and Causes of a Decline to Hoehn and Yahr Stage 5 in Patients with Parkinson's Disease.

Publication Type: Academic Journal

Source(s): Internal medicine (Tokyo, Japan) [Intern Med] 2023 Mar 01; Vol. 62 (5), pp. 711-716. Date of Electronic Publication: 2022 Aug 10.

Abstract: Objective Prediction of time until and causes of becoming bedridden may help patients with Parkinson's disease (PD) plan their productive lives. This study assessed the relationship between the age at the PD onset and time taken to reach Hoehn and Yahr...

Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials.

Publication Type: Academic Journal

Source(s): Journal of pharmacokinetics and pharmacodynamics [J Pharmacokinet Pharmacodyn] 2023 Feb; Vol. 50 (1), pp. 45-62. Date of Electronic Publication: 2023 Jan 04.

Abstract: Clinical Dementia Rating-Sum of Boxes (CDR-SB) assessments from two Phase 3 studies (ENGAGE and EMERGE) of aducanumab in subjects with early Alzheimer's disease (AD) were pooled to develop an exposure-response (ER) model. A linear model in the logit-tr...

Mitochondrial haplogroups and cognitive progression in Parkinson's disease.

Publication Type: Academic Journal

Source(s): Brain : a journal of neurology [Brain] 2023 Jan 05; Vol. 146 (1), pp. 42-49.

Authors:

Abstract: Mitochondria are a culprit in the onset of Parkinson's disease, but their role during disease progression is unclear. Here we used Cox proportional hazards models to exam the effect of variation in the mitochondrial genome on longitudinal cognitive and...

The dilemma between milestones of progression versus clinical scales in Parkinson's disease.

Publication Type: Academic Journal

Source(s): Handbook of clinical neurology [Handb Clin Neurol] 2023; Vol. 192, pp. 169-185.

Abstract: There are significant challenges in accurately documenting the progression of Parkinson's disease (PD). The disease course is highly heterogeneous, there are no validated biomarkers, and we are reliant on repeated clinical measures to assess disease st...

sponsored